Thuringian company revolutionizes eye examinations with novelty!

Thuringian company revolutionizes eye examinations with novelty!

In an exciting step in the world of ophthalmology, the Beteiligungmanagement Thuringia GmbH (bm | t) and the Sparkasse Jena-Saale-Holzland involved in a seed-financing round of perceptec GmbH. The young company, which was only founded in May 2024, works on an innovative, software -based solution to assess visual defects by a virtual eye test.

The financing, which is moving in the middle six -digit range, aims to bring the product to market maturity and successfully promote clinical validations and medical approvals. "We want to revolutionize the outdated, time -consuming eye examinations," explains Dr. Markus Leicht, CEO from perceptec. The use of 3D display technology enables users to carry out the test independently, which significantly improves accessibility.

an important step in ophthalmology

Imagine that only 36 % of the 2.2 billion people with visual impairments worldwide have access to adequate diagnostics. These alarming numbers provided by the WHO show the urgency for innovative solutions in ophthalmology. The WHO emphasizes that historical successes, including inexpensive surgical approaches such as the manual small incision cataract operations, are not sufficient to make the necessary progress.

PerceptTec GmbH could be a key player here by potentially replacing up to 85,000 classic vision devices with its new test solution. The focus is initially on the roof+room, with long-term plans for expansion to further European and international markets.

technological progress and their importance

Progress in ophthalmology is not only driven by new products, but also by technological innovations. As medtec solutions is a growing need for innovative to observe ophthalmological devices and treatments. Advances such as Optical Coherence Tomography (OCT) and liquid -based diagnostic techniques revolutionize the way structural health problems are diagnosed in ophthalmology.

In addition, the use of artificial intelligence is becoming increasingly relevant. It improves efficiency in diagnostics and enables more precise treatment decisions. The combination of telemedicine with advanced diagnostic tools could revolutionize eye care-and the perceptec solution could offer exactly that.

Another advantage of this technology is to consider mobile variants for screenings in schools or rural regions. In view of the prevailing barriers, such as costs and physical distance from the providers of eye care, this is a pioneering approach to give more people access.

With the planned second finance round by September 2025 and the use of funding from the FTI-Thuringia Technology program, Perceptec plans to win over other private investors to advance their mission. You have a good knack for steering ophthalmology in a new direction and fully exploiting the potential of the technology.